Aveanna Healthcare (NASDAQ:AVAH) Price Target Lowered to $9.50 at Barclays

Key Points

• Barclays cut its price target on Aveanna Healthcare from $11.00 to $9.50 while keeping an overweight rating, implying roughly a 41.7% upside from the prior close.
• Analyst consensus is a Moderate Buy with an average price target of $10.38, reflecting mixed ratings across firms (1 Strong Buy, 5 Buy, 5 Hold).
• Insiders have sold about 998,595 shares worth ~$7.57 million in the last three months, and insiders now own approximately 7.00% of the company.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) had its target price decreased by Barclays from $11.00 to $9.50 in a report released on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's price objective would suggest a potential upside of 41.69% from the company's previous close.

A number of other research analysts have also issued reports on the company. Royal Bank Of Canada dropped their price target on shares of Aveanna Healthcare from $11.00 to $9.00 and set a "sector perform" rating on the stock in a research report on Monday. Truist Financial reduced their price target on shares of Aveanna Healthcare from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Friday, March 20th. UBS Group upped their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a "neutral" rating in a research note on Thursday, January 15th. William Blair started coverage on Aveanna Healthcare in a research note on Monday, December 8th. They issued an "outperform" rating on the stock. Finally, Raymond James Financial upgraded Aveanna Healthcare from an "outperform" rating to a "strong-buy" rating and set a $13.00 price target for the company in a research note on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $10.38.

Aveanna Healthcare Stock Up 1.4%

Shares of Aveanna Healthcare stock opened at $6.71 on Wednesday. Aveanna Healthcare has a twelve month low of $3.73 and a twelve month high of $10.32. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of 6.55 and a beta of 2.07. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 6.62. The business's 50 day simple moving average is $7.76 and its 200-day simple moving average is $8.47.

Insider Transactions at Aveanna Healthcare

In related news, CAO Deborah Stewart sold 11,181 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $80,615.01. Following the sale, the chief accounting officer owned 301,807 shares of the company's stock, valued at $2,176,028.47. The trade was a 3.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patrick A. Cunningham sold 18,436 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $132,923.56. Following the transaction, the insider owned 337,755 shares of the company's stock, valued at $2,435,213.55. This represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 998,595 shares of company stock worth $7,567,770. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd raised its position in shares of Aveanna Healthcare by 8.9% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company's stock valued at $126,000 after acquiring an additional 1,151 shares during the last quarter. Barclays PLC increased its stake in Aveanna Healthcare by 0.8% during the 3rd quarter. Barclays PLC now owns 179,359 shares of the company's stock worth $1,591,000 after purchasing an additional 1,366 shares in the last quarter. Franklin Resources Inc. raised its holdings in Aveanna Healthcare by 4.5% during the 3rd quarter. Franklin Resources Inc. now owns 35,630 shares of the company's stock worth $316,000 after buying an additional 1,528 shares during the period. Intech Investment Management LLC increased its position in shares of Aveanna Healthcare by 9.8% during the fourth quarter. Intech Investment Management LLC now owns 19,483 shares of the company's stock worth $159,000 after acquiring an additional 1,739 shares in the last quarter. Finally, Balboa Wealth Partners raised its holdings in shares of Aveanna Healthcare by 13.5% during the fourth quarter. Balboa Wealth Partners now owns 16,890 shares of the company's stock worth $138,000 after acquiring an additional 2,007 shares during the period. 87.96% of the stock is currently owned by institutional investors.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc NASDAQ: AVAH is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.